LENZ Earnings Prediction
The chart below shows how LENZ performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LENZ sees a +10.54% change in stock price 10 days leading up to the earnings, and a -3.83% change 10 days following the report. On the earnings day itself, the stock moves by -1.25%. This data can give you a slight idea of what to expect for the next quarter's release.
LENZ Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.38
-86.18%
-5.00%
No Data Available
LENZ Earnings Analysis
LENZ Therapeutics, Inc. Common Stock Corporation (LENZ.O) Earnings Conference Call
Positive
Corporate Achievements Highlighted: The third quarter of 2024 has been highlighted by multiple significant corporate achievements.
PIPE Financing Success: We completed a $30 million PIPE financing with Ridgeback, bringing in a strong and well-respected investor into our shareholder base.
Cash and Marketable Securities: We ended the third quarter 2024 with approximately $217.2 million in cash, cash equivalents, and marketable securities.
Operating Expenses Reduction: Total operating expenses for Q3 2024 were approximately $12.9 million compared to $19.9 million for the same period in 2023, reflecting effective cost management.
R&D Expense Reduction: Total R&D expenses decreased to $6.5 million in Q3 2024 compared to $17 million for the same period in 2023.
Negative
Operating Expenses Decrease: Total operating expenses for Q3 2024 were approximately $12.9 million compared to $19.9 million for the same period in 2023, indicating a significant decrease in expenses but still reflecting a cash burn of approximately $9 million.
R&D Expense Reduction: Total R&D expenses decreased to $6.5 million in Q3 2024 compared to $17 million for the same period in 2023, showing a substantial reduction in investment in research and development.
SG&A Expense Increase: Total SG&A expenses increased to $6.5 million in Q3 2024 compared to $2.9 million for the same period in 2023, indicating a significant rise in selling, general, and administrative costs.
Net Loss Comparison: Net loss per share was $0.38 in Q3 2024 on a net loss of $10.2 million compared to a net loss per share of $9.62 in Q3 2023 on a net loss of $18.9 million, reflecting ongoing financial challenges.
Cash Burn and Losses: Operating expenses and resulting cash burn for the third quarter were once again substantially in line with our plan, but the overall financial results indicate continued losses and cash flow concerns.
LENZ FAQs
How does LENZ typically perform around its earnings report dates?
Is LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LENZ Earning Call Sentiment
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LENZ.O
-0.44%Positive
The earnings call summary indicates strong financial health with a stable cash position and reduced net loss. The recent PIPE financing enhances the shareholder base, and decreased operating expenses suggest efficient cost management. Although the Q&A section revealed some unclear responses, the overall sentiment remains positive due to optimistic product positioning and extensive preparation for the LNZ100 launch. The management's strategic focus on a robust supply chain and marketing efforts further supports a positive outlook. The absence of significant negative factors suggests a stock price increase in the 2% to 8% range.
